The antioxidant 2,3‐dichloro,5,8‐dihydroxy,1,4‐naphthoquinone inhibits acetyl‐cholinesterase activity and amyloid β42 aggregation: A dual target therapeutic candidate compound for the treatment of Alzheimer's disease
Sign Up to like & getrecommendations! Published in 2019 at "Biotechnology and Applied Biochemistry"
DOI: 10.1002/bab.1870
Abstract: Alzheimer's disease is characterized by amyloid β aggregation and cholinergic neurodegeneration. In the present study, pure DDN (2,3‐dichloro‐5,8‐dihydroxy‐1,4‐naphthoquinone) was examined, for the first time, for its dual potential as inhibitor of acetylcholinesterase (AChE) and Aβ42… read more here.
Keywords: aggregation; dichloro dihydroxy; dihydroxy naphthoquinone; alzheimer disease ... See more keywords